Top

BMC Nephrology

Published in:

Open Access 01-12-2022 | Cytokines | Research

The effect of BKV reactivation on cytokines behavior in kidney transplanted patients

Authors: Zahra Rahimi, Ramin Yaghobi, Afsoon Afshari, Jamshid Roozbeh, Mohammad Javad Mokhtari, Ali Malek Hosseini

Published in: BMC Nephrology | Issue 1/2022

Abstract

Background

BK virus associated nephropathy (BKVAN) is one of the common causes of graft loss among kidney transplanted recipients (KTRs). The current treatment for BKV nephropathy is decreasing the immunosuppressive regimen in KTRs. Interleukin-27 (IL-27) is a multifunctional cytokine that might be the front-runner of an important pathway in this regard. Therefore, in current study it is tried to evaluate the changes in the expression level of IL-27 and some related molecules, resulting from BKV reactivation in KTR patients.

Methods

EDTA-treated blood samples were collected from all participants. Patients were divided into two groups, 31 kidney transplant recipients with active and 32 inactive BKV infection, after being monitored by Real time PCR (Taq-Man) in plasma. Total of 30 normal individuals were considered as healthy control group. Real time PCR (SYBR Green) technique is used to determine the expression level of studied genes.

Results

The results of gene expression comparisons showed that the expression level of IL-27, IFN-γ, TNF-α, TNFR2 and IRF7 genes was significantly higher in inactive group in comparison to active group. The expression level of TLR4 was lower in both active and inactive groups in comparison to control group. ROC curve analysis showed that IL-27 and IRF7 are significantly different amongst other studied genes. Finally, the analyses revealed that the expression level of most of the studied genes (except for TNF-α and TLR4) have significant correlation with viral load.

Conclusions

Our findings revealed that IL-27, IFN-γ, TNF-α, TNFR2 and IRF7 expression level is higher in inactive group and TLR4 expression level is lower in patients’ groups in comparison to control group. Also, ROC curve analysis showed IL-27 and IRF7 can significantly differentiate studied groups (BKV active vs. inactive). Therefore, these results might help elucidating the pattern in charge of BKV reactivation in kidney transplanted patients.

Available only for authorised users

Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation. 2009;87:621–30. https://doi.org/10.1097/TP.0b013e318197c17d.CrossRefPubMed

van Aalderen MC, Heutinck KM, Huisman C, ten Berge IJ. BK virus infection in transplant recipients: clinical manifestations, treatment options and the immune response. Neth J Med. 2012;70(4):172–83.PubMed

Lamarche C, Orio J, Collette S, Senécal L, Hébert MJ, Renoult É, et al. BK Polyomavirus and the transplanted kidney: immunopathology and therapeutic approaches. Transplantation. 2016;100:2276–87. https://doi.org/10.1097/TP.0000000000001333.CrossRefPubMedPubMedCentral

Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+T cells. Immunity. 2002;16:779–90. https://doi.org/10.1016/S1074-7613(02)00324-2.CrossRefPubMed

Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, Kieff E, et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol. 1996;70:1143–53. https://doi.org/10.1128/jvi.70.2.1143-1153.1996.CrossRefPubMedPubMedCentral

Lubetzky M, Bao Y, Ó Broin P, Marfo K, Ajaimy M, Aljanabi a, et al. genomics of BK viremia in kidney transplant recipients. Transplantation. 2014;97:451–456. doi:https://doi.org/10.1097/01.TP.0000437432.35227.3e.

Kariminik A, Yaghobi R, DabIrI S. Innate immunity and BK virus: prospective strategies. Viral Immunol. 2016;29:74–82. https://doi.org/10.1089/vim.2015.0099.CrossRefPubMed

Jonjić S, Babić M, Polić B, Krmpotić A. Immune evasion of natural killer cells by viruses. Curr Opin Immunol. 2008;20:30–8. https://doi.org/10.1016/j.coi.2007.11.002.CrossRefPubMedPubMedCentral

Hesselink DA, Vaessen LMB, Hop WCJ, Schoordijk W, Ijzermans JNM, Baan CC, et al. The effects of renal transplantation on circulating dendritic cells. Clin Exp Immunol. 2005;140:384–93. https://doi.org/10.1111/j.1365-2249.2005.02755.x.CrossRefPubMedPubMedCentral

10.

Womer KL, Peng R, Patton PR, Murawski MR, Bucci M, Kaleem A, et al. The effects of renal transplantation on peripheral blood dendritic cells. Clin Transpl. 2005;19:659–67. https://doi.org/10.1111/j.1399-0012.2005.00405.x.CrossRef

11.

Comoli P, Cioni M, Basso S, Gagliardone C, Potenza L, Verrina E, et al. Immunity to polyomavirus BK infection: immune monitoring to regulate the balance between risk of BKV nephropathy and induction of alloimmunity. Clin Dev Immunol. 2013;2013. https://doi.org/10.1155/2013/256923.

12.

Ambalathingal GR, Francis RS, Smyth MJ, Smith C, Khanna R. BK polyomavirus: clinical aspects, immune regulation, and emerging therapies. Clin Microbiol Rev. 2017;30:503–28. https://doi.org/10.1128/CMR.00074-16.CrossRefPubMedPubMedCentral

13.

O’Donnell CD, Vogel L, Wright A, Das SR, Wrammert J, Li GM, et al. Antibody pressure by a human monoclonal antibody targeting the 2009 pandemic H1N1 virus hemagglutinin drives the emergence of a virus with increased virulence in mice. MBio. 2012;3. https://doi.org/10.1128/mBio.00120-12.

14.

Pastrana DV, Ray U, Magaldi TG, Schowalter RM, Cuburu N, Buck CB. BK Polyomavirus genotypes represent distinct serotypes with distinct entry tropism. J Virol. 2013;87:10105–13. https://doi.org/10.1128/jvi.01189-13.CrossRefPubMedPubMedCentral

15.

Ginevri F, Azzi A, Hirsch HH, Basso S, Fontana I, Cioni M, et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant. 2007;7:2727–35. https://doi.org/10.1111/j.1600-6143.2007.01984.x.CrossRefPubMed

16.

Schachtner T, Müller K, Stein M, Diezemann C, Sefrin A, Babel N, et al. BK virus-specific immunity kinetics: a predictor of recovery from Polyomavirus BK-associated nephropathy. Am J Transplant. 2011;11:2443–52. https://doi.org/10.1111/j.1600-6143.2011.03693.x.CrossRefPubMed

17.

Chen Y, Trofe J, Gordon J, Du Pasquier RA, Roy-Chaudhury P, Kuroda MJ, et al. Interplay of cellular and Humoral immune responses against BK virus in kidney transplant recipients with Polyomavirus nephropathy. J Virol. 2006;80:3495–505. https://doi.org/10.1128/jvi.80.7.3495-3505.2006.CrossRefPubMedPubMedCentral

18.

Hammer MH, Brestrich G, Andree H, Engelmann E, Rosenberger C, Tillmann H, et al. HLA type-independent method to monitor Polyoma BK virus-specific CD4 ⁺ and CD8 ⁺ T-cell immunity. Am J Transplant. 2006;6:625–31. https://doi.org/10.1111/j.1600-6143.2005.01221.x.CrossRefPubMed

19.

Binggeli S, Egli A, Schaub S, Binet I, Mayr M, Steiger J, et al. Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant. 2007;7:1131–9. https://doi.org/10.1111/j.1600-6143.2007.01754.x.CrossRefPubMed

20.

Renner FC, Dietrich H, Bulut N, Celik D, Freitag E, Gaertner N, et al. The risk of polyomavirus-associated graft nephropathy is increased by a combined suppression of cd8 and cd4 cell-dependent immune effects. In: Transplantation Proceedings. Elsevier; 2013. p. 1608–1610.

21.

Schaenman JM, Korin Y, Sidwell T, Kandarian F, Harre N, Gjertson D, et al. Increased frequency of BK virus-specific Polyfunctional CD8+ T cells predict successful control of BK Viremia after kidney transplantation. Transplantation. 2017;101:1479–87. https://doi.org/10.1097/TP.0000000000001314.CrossRefPubMedPubMedCentral

22.

Mueller K, Schachtner T, Sattler A, Meier S, Friedrich P, Trydzenskaya H, et al. BK-VP3 as a new target of cellular immunity in BK virus infection. Transplantation. 2011;91:100–7. https://doi.org/10.1097/TP.0b013e3181fe1335.CrossRefPubMed

23.

Zhou W, Sharma M, Martinez J, Srivastava T, Diamond DJ, Knowles W, et al. Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults. Viral Immunol. 2007;20:379–88. https://doi.org/10.1089/vim.2007.0030.CrossRefPubMed

24.

Trydzenskaya H, Juerchott K, Lachmann N, Kotsch K, Kunert K, Weist B, et al. The genetic predisposition of natural killer cell to BK virus-associated nephropathy in renal transplant patients. Kidney Int. 2013;84:359–65. https://doi.org/10.1038/ki.2013.59.CrossRefPubMed

25.

Weist BJD, Schmueck M, Fuehrer H, Sattler A, Reinke P, Babel N. The role of CD4+T cells in BKV-specific T cell immunity. Med Microbiol Immunol. 2014;203:395–408. https://doi.org/10.1007/s00430-014-0348-z.CrossRefPubMed

26.

Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol. 2005;5:521–31. https://doi.org/10.1038/nri1648.CrossRefPubMed

27.

Sprecher CA, Grant FJ, Baumgartner JW, Presnell SR, Schrader SK, Yamagiwa T, et al. Cloning and characterization of a novel class I cytokine receptor. Biochem Biophys Res Commun. 1998;246:82–90. https://doi.org/10.1006/bbrc.1998.8576.CrossRefPubMed

28.

Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 2003;170:4886–4890. http://www.ncbi.nlm.nih.gov/pubmed/12734330. Accessed 30 Jul 2017.

29.

Cao Y, Zhang R, Zhang W, Zhu C, Yu Y, Song Y, et al. IL-27, a cytokine, and IFN-λ1, a type III IFN, are coordinated to regulate virus replication through type I IFN. J Immunol. 2014;192:691–703. https://doi.org/10.4049/jimmunol.1300252.CrossRefPubMed

30.

Zare A, Karimi MH, Rashki A, Geramizadeh B, Afshari A, Miri HR, et al. Association of the Interleukin-27 gene expression and hepatitis B virus infection in liver transplanted patients. Exp Clin Transplant. 2016. https://doi.org/10.6002/ect.2015.0243.

31.

Frank AC, Zhang X, Katsounas A, Bharucha JP, Kottilil S, Imamichi T. Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. J Interf Cytokine Res. 2010;30:427–31. https://doi.org/10.1089/jir.2009.0093.CrossRef

32.

Comoli P, Azzi A, Maccario R, Basso S, Botti G, Basile G, et al. Polyomavirus BK-specific immunity after kidney transplantation. Transplantation. 2004;78:1229–32. https://doi.org/10.1097/01.TP.0000137932.44791.D3.CrossRefPubMed

33.

Chakera A, Bennett S, Lawrence S, Morteau O, Mason PD, O’Callaghan CA, et al. Antigen-specific T cell responses to BK polyomavirus antigens identify functional anti-viral immunity and may help to guide immunosuppression following renal transplantation. Clin Exp Immunol. 2011;165:401–9. https://doi.org/10.1111/j.1365-2249.2011.04429.x.CrossRefPubMedPubMedCentral

34.

Murphy KM, Ouyang W, Farrar JD, Yang J, Ranganath S, Asnagli H, et al. Signaling and transcription in T helper development. Annu Rev Immunol. 2000;18:451–94. https://doi.org/10.1146/annurev.immunol.18.1.451.CrossRefPubMed

35.

Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002;16:779–790. http://www.ncbi.nlm.nih.gov/pubmed/12121660. Accessed 30 Jul 2017.

36.

Schneider R, Yaneva T, Beauseigle D, El-Khoury L, Arbour N. IL-27 increases the proliferation and effector functions of human naïve CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur J Immunol. 2011;41:47–59. https://doi.org/10.1002/eji.201040804.CrossRefPubMed

37.

Larousserie F, Charlot P, Bardel E, Froger J, Kastelein RA, Devergne O. Differential effects of IL-27 on human B cell subsets. J Immunol. 2006;176:5890–7. https://doi.org/10.4049/jimmunol.176.10.5890.CrossRefPubMed

38.

Charlot-Rabiega P, Bardel E, Dietrich C, Kastelein R, Devergne O. Signaling events involved in interleukin 27 (IL-27)-induced proliferation of human naive CD4 + T cells and B cells. J Biol Chem. 2011;286:27350–62. https://doi.org/10.1074/jbc.M111.221010.CrossRefPubMedPubMedCentral

39.

Hall AOH, Silver JS, Hunter CA. The Immunobiology of IL-27. In: Advances in Immunology. Academic Press Inc.; 2012. p. 1–44. https://doi.org/10.1016/B978-0-12-394299-9.00001-1.CrossRef

40.

Sun J, Dodd H, Moser EK, Sharma R, Braciale TJ. CD4+ T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs. Nat Immunol. 2011;12:327–35. https://doi.org/10.1038/ni.1996.CrossRefPubMedPubMedCentral

41.

Anderson CF, Stumhofer JS, Hunter CA, Sacks D. IL-27 regulates IL-10 and IL-17 from CD4 + cells in nonhealing Leishmania major infection. J Immunol. 2009;183:4619–27. https://doi.org/10.4049/jimmunol.0804024.CrossRefPubMed

42.

Villarino AV, Gallo E, Abbas AK. STAT1-activating cytokines limit Th17 responses through both T-bet–dependent and –independent mechanisms. J Immunol. 2010;185:6461–71. https://doi.org/10.4049/jimmunol.1001343.CrossRefPubMed

43.

Yoshimura T, Takeda A, Hamano S, Miyazaki Y, Kinjyo I, Ishibashi T, et al. Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4 + T cells versus suppression of Proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4 + T cells partially through STAT3-dependent mechanism. J Immunol. 2006;177:5377–85. https://doi.org/10.4049/jimmunol.177.8.5377.CrossRefPubMed

44.

Fujita H, Teng A, Nozawa R, Takamoto-Matsui Y, Katagiri-Matsumura H, Ikezawa Z, et al. Production of both IL-27 and IFN-γ after the treatment with a ligand for invariant NK T cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model. J Immunol. 2009;183:254–60. https://doi.org/10.4049/jimmunol.0800520.CrossRefPubMed

45.

Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, Narita M, et al. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol - Gastrointest Liver Physiol. 2011;300:G568–76. https://doi.org/10.1152/ajpgi.00329.2010.CrossRefPubMed

46.

Villarino A, Hibbert L, Lieberman L, Wilson E, Mak T, Yoshida H, et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity. 2003;19:645–655. http://www.ncbi.nlm.nih.gov/pubmed/14614852. Accessed 30 Jul 2017.

47.

Villarino AV, Stumhofer JS, Saris CJM, Kastelein RA, de Sauvage FJ, Hunter CA. IL-27 limits IL-2 production during Th1 differentiation. J Immunol. 2006;176:237–47. https://doi.org/10.4049/jimmunol.176.1.237.CrossRefPubMed

48.

Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol. 2006;7:937–45. https://doi.org/10.1038/ni1376.CrossRefPubMed

49.

Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell. 2006;22:561–9. https://doi.org/10.1016/j.molcel.2006.05.012.CrossRefPubMed

50.

Robson MG. Toll-like receptors and renal disease. Nephron Exp Nephrol. 2009;113:e1–7. https://doi.org/10.1159/000228077.CrossRefPubMed

51.

Hashimoto SI, Suzuki T, Nagai S, Yamashita T, Toyoda N, Matsushima K. Identification of genes specifically expressed in human activated and mature dendritic cells through serial analysis of gene expression. Blood. 2000;96:2206–14. https://doi.org/10.1182/blood.v96.6.2206.CrossRefPubMed

52.

Liu J, Guan X, Ma X. Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-γ-mediated pathways. J Exp Med. 2007;204:141–52. https://doi.org/10.1084/jem.20061440.CrossRefPubMedPubMedCentral

53.

Wirtz S, Becker C, Fantini MC, Nieuwenhuis EE, Tubbe I, Galle PR, et al. EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-κB activation. J Immunol. 2005;174:2814–24. https://doi.org/10.4049/jimmunol.174.5.2814.CrossRefPubMed

54.

Molle C, Nguyen M, Flamand V, Renneson J, Trottein F, De Wit D, et al. IL-27 synthesis induced by TLR ligation critically depends on IFN regulatory factor 3. J Immunol. 2007;178:7607–15. https://doi.org/10.4049/jimmunol.178.12.7607.CrossRefPubMed

55.

Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, et al. LPS-TLR4 signaling to IRF-3/7 and NF-κB involves the toll adapters TRAM and TRIF. J Exp Med. 2003;198:1043–55. https://doi.org/10.1084/jem.20031023.CrossRefPubMedPubMedCentral

56.

Molle C, Goldman M, Goriely S. Critical role of the IFN-stimulated gene factor 3 complex in TLR-mediated IL-27p28 gene expression revealing a two-step activation process. J Immunol. 2010;184:1784–92. https://doi.org/10.4049/jimmunol.0902005.CrossRefPubMed

57.

Zhang L, Pagano JS. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. Mol Cell Biol. 1997;17:5748–57. https://doi.org/10.1128/mcb.17.10.5748.CrossRefPubMedPubMedCentral

58.

Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK, Archer DR, et al. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity. 2000;13:129–41. https://doi.org/10.1016/S1074-7613(00)00014-5.CrossRefPubMed

59.

Chattopadhyay S, Veleeparambil M, Poddar D, Abdulkhalek S, Bandyopadhyay SK, Fensterl V, et al. EGFR kinase activity is required for TLR4 signaling and the septic shock response. EMBO Rep. 2015;16:1535–47. doi:https://doi.org/10.15252/embr.201540337.

60.

Antonczyk A, Krist B, Sajek M, Michalska A, Piaszyk-Borychowska A, Plens-Galaska M, et al. Direct inhibition of IRF-dependent transcriptional regulatory mechanisms associated with disease. Front Immunol. 2019;1176. doi:https://doi.org/10.3389/fimmu.2019.01176.

Title: The effect of BKV reactivation on cytokines behavior in kidney transplanted patients
Authors: Zahra Rahimi
Ramin Yaghobi
Afsoon Afshari
Jamshid Roozbeh
Mohammad Javad Mokhtari
Ali Malek Hosseini
Publication date: 01-12-2022
Publisher: BioMed Central
Keyword: Cytokines
Published in: BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-021-02645-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Use of low-protein staple foods in the dietary management of patients with stage 3–4 chronic kidney disease: a prospective case-crossover study

Correction: Does conservative kidney management offer a quantity or quality of life benefit compared to dialysis? a systematic review

Development of a europium nanoparticles lateral flow immunoassay for NGAL detection in urine and diagnosis of acute kidney injury

Self-management program for patients with chronic kidney disease (SMP-CKD) in Southern China: protocol for an ambispective cohort study

Sunitinib-related high-grade proteinuria and allograft dysfunction in a kidney recipient: a rare case report

IgA vasculitis presenting as nephrotic syndrome following COVID-19 vaccination: a case report

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage